Shares of CRISPR Therapeutics (NASDAQ: CRSP) are down nearly 17% over the past year but up over 16% so far in 2023. The clinical-stage biotech company is named for the CRISPR/Cas9 gene-editing method that won the Nobel Prize for chemistry in 2020, and the buzz for the company seems to be growing.

CRISPR is an acronym for clustered regularly inter-spaced short palindromic repeats, which are found in the DNA gene sequences of prokaryotic organisms, such as bacteria or archaea, a group of single-celled organisms.

The company is looking to CRISPR/Cas9 gene editing to find therapies for a multitude of maladies. It is working on therapies in four areas:

Continue reading

Source Fool.com